Juvelook vs Exosomes: How Are They Regulated?

Juvelook vs Exosomes: How Are They Regulated?

Kim Simon Jang-ju26 min readEditorial policy

Key takeaways

  • Juvelook: the 50 mg vial holds 42.5 mg of PDLLA and 7.5 mg of non-cross-linked HA (the line also includes other sizes such as Juvelook Volume), and the manufacturer's page lists its use in Korea as injection under the skin for temporary improvement of facial wrinkles in adults.
  • Exosomes: tiny extracellular vesicles from different cell types; products differ in source, and many cosmetic products give little information on how they were made.
  • FDA status: the FDA says exosome products meant to treat diseases or conditions generally need FDA approval, and that there are currently no FDA-approved exosome products.
  • Evidence: human studies on exosomes for skin are few and small; Juvelook's published evidence is also small and partly supported by its manufacturer.
  • If you are treated abroad: the FDA advises learning the rules that cover products in that country, since it has no oversight there.

Juvelook and exosomes sit in different places when it comes to regulation: Juvelook is a named product line with stated contents, PDLLA microspheres with a small amount of non-cross-linked hyaluronic acid (HA), which its manufacturer describes as a class 4 medical device approved by Korea's Ministry of Food and Drug Safety with a specific listed use, while the U.S. FDA states that there are currently no FDA-approved exosome products. Exosomes are tiny vesicles released by cells, and the products sold under that name differ in source and processing, so the first thing to pin down is what exactly is being offered and what it is registered for.

There are other ways to compare two skin treatments, but this article uses one: what each one is and how it is regulated. It is not a ranking, it does not say which one works better, and the studies below were done under their own conditions, not at STON Clinic.

What Is Juvelook, and What Is Its Listed Use?

What Is Juvelook, and What Is Its Listed Use?What Is Juvelook, and What Is Its Listed Use?

Juvelook is a polylactic acid injectable. A 2025 lab comparison of polylactic acid injectables places it with the PDLLA products, poly(D,L-lactic acid), and notes that it carries its particles in non-cross-linked HA, where the other products in that comparison use a cellulose gel called CMC. Like the others, it is reconstituted with sterile water for injection before use.

A 2026 study of 15 women, supported by the manufacturer VAIM, gives the amounts in the 50 mg vial: 42.5 mg of PDLLA with 7.5 mg of non-cross-linked HA. The manufacturer's Korean product page lists the same split for its 50 mg product, and the line also includes other sizes, such as Juvelook Volume. On the regulatory side, that page describes Juvelook as a class 4 medical device approved by the Ministry of Food and Drug Safety and lists the intended use of the products in the line as injection of polylactide and hyaluronic acid under the skin for temporary improvement of facial wrinkles in adults. That is a named product line with stated contents and a written intended use, which is the starting point for comparing it with exosomes.

What Are Exosomes?

What Are Exosomes?What Are Exosomes?

A 2026 systematic review describes exosomes as tiny extracellular vesicles, small packets released by different cell types. In skin studies they come from several sources: a 2026 scoping review of topical exosomes found studies using both human and plant-derived exosomes, and a second 2026 scoping review found that most sources were mesenchymal stem cells, delivered by topical application, microneedling, fractional CO2 laser or injection.

The word "exosome" therefore does not name one product. The topical review also looked at 20 commercially available cosmetic products and found that they varied in exosome source and gave minimal information on isolation, processing or shelf life. Two treatments both called "exosomes" may contain different things.

How Does the FDA Regulate Exosome Products?

How Does the FDA Regulate Exosome Products?How Does the FDA Regulate Exosome Products?

The FDA's consumer alert on regenerative medicine products says that exosome products are regulated by the FDA, that as a general matter exosome products intended to treat diseases or conditions in humans require FDA approval, and that there are currently no FDA-approved exosome products. It also warns that there is a lot of misleading information on the internet about these products.

A separate FDA public safety notification on exosome products from December 2019 describes multiple reports of serious adverse events in patients in Nebraska who were treated with unapproved products marketed as containing exosomes. For patients in the United States, it suggests asking whether the FDA has reviewed the treatment.

These FDA statements are about exosome products in the United States. They do not describe Juvelook, and they do not tell you how a given product is registered in Korea.

How Does the FDA Regulate Exosome Products?How Does the FDA Regulate Exosome Products?

The sketch only shows the difference in form: a named product line with stated contents on one side, and vesicles that studies deliver in several ways on the other. Sizes and depths are not drawn to scale.

Juvelook and Exosomes Side by Side

Juvelook and Exosomes Side by SideJuvelook and Exosomes Side by Side

JuvelookExosome productsSource
What it isPDLLA microspheres with non-cross-linked HA; the 50 mg vial holds 42.5 mg and 7.5 mgTiny extracellular vesicles from different cell typesPMC13433536, manufacturer page, PMID 41912205
Source or formA named product line with stated contents, mixed with sterile water before useHuman or plant sources, mostly mesenchymal stem cells in studiesPMC12787764, PMID 42411735, PMID 41931695
How it is givenInjected under the skinTopical, microneedling, fractional CO2 laser or injection in studiesManufacturer page, PMID 41931695
Listed use or statusKorea: class 4 medical device; temporary improvement of facial wrinkles in adultsUnited States: no FDA-approved exosome productsManufacturer page, FDA

These rows describe the products and their status, not results, and they say nothing about which one suits a given face.

What Does the Research Show So Far?

What Does the Research Show So Far?What Does the Research Show So Far?

For exosomes, the topical scoping review screened 2,394 articles and found 18 that tested topical exosomes for skin rejuvenation; 10 combined them with a delivery method and 8 used topical application alone. Its authors conclude that human studies remain scarce and that much of the current evidence is extrapolated from preclinical models. The second scoping review found 17 human studies from 2020 to 2025, including cohort studies, comparative trials and case series, and lists small sample sizes, short follow-up, non-randomized single-arm designs and potential conflicts of interest as limits. The 2026 systematic review calls for standardized trials with larger cohorts and longer follow-up to confirm efficacy and long-term safety.

For Juvelook, the studies cited here are lab work, case reports, the 15-woman study and a preliminary study of 16 patients using combined PDLLA and non-cross-linked HA (its abstract does not name the brand). The 15-woman study was supported by VAIM, and both of its authors had received speaker honoraria from VAIM. A 2025 case report describes the PDLLA in Juvelook as the part meant to stimulate collagen.

No study cited here compared Juvelook and exosomes directly. These are results under each study's conditions and are not STON Clinic results.

Which Side Effects Have Been Reported?

For exosomes, the second scoping review reports that adverse events were uncommon but included granulomas, necrosis and allergic reactions after injection. The FDA safety notification adds the reports of serious adverse events with unapproved products marketed as containing exosomes.

For polylactic acid products, the lab comparison notes that bruising, swelling, nodules, papules under the skin and granulomas may result from poor spreading of the microspheres or too little dilution, and a 2025 case report describes firm nodules 3 weeks after PDLLA (Juvelook) injections under the eyes. A 2026 expert consensus on PDLLA-HA 200 (Juvelook Volume) describes visual field impairment and blindness from accidental injection into a blood vessel as a rare but devastating complication. These come from different study conditions, so they are not a side-by-side comparison. The FDA's patient page on dermal fillers notes that filler side effects may appear weeks, months or years later, and advises seeking immediate medical attention for unusual pain, vision changes, a white, gray or blue look to the skin near the injection site, or any signs of a stroke.

Questions to Ask If You Are Treated in Korea

The FDA notification gives advice for people considering an exosome product in another country: learn about the regulations that cover products in that country, and know that the FDA does not have oversight of treatments done in other countries. The same habit works for any injectable, Juvelook included: ask for the product name and what it is registered for where you are being treated.

Questions to Ask If You Are Treated in KoreaQuestions to Ask If You Are Treated in Korea

STON Clinic's Juvelook Page

STON Clinic's Juvelook page describes it as a skin booster using an injectable product that contains PDLLA and hyaluronic acid. According to the page, more than one product carries the Juvelook name, and which one is used is decided at the exam after looking at the skin.

STON Clinic is on the 9th floor of Lotte Hotel Seoul Main Tower, near Euljiro 1(il)-ga Station, and consultations are available in English.

Summary: Start With What It Is and What It Is Registered For

Juvelook is a named product line with stated contents, PDLLA microspheres with a little non-cross-linked HA, which its manufacturer describes as a class 4 medical device with a listed use in Korea for temporary improvement of facial wrinkles in adults. Exosomes are tiny vesicles from various sources, the products called by that name vary, and the FDA says there are currently no FDA-approved exosome products. Human evidence on exosomes is small and the Juvelook studies cited here are also small, so the product name, its registration and whether it suits you are worth settling at an in-person exam.

Quick booking

References

  1. 2025 lab comparison of polylactic acid injectables — PubMed Central
  2. 2026 study of 15 women — PubMed Central
  3. 2026 systematic review — PubMed Central
  4. 2026 scoping review of topical exosomes — PubMed Central
  5. second 2026 scoping review — PubMed Central
  6. consumer alert on regenerative medicine products — U.S. Food and Drug Administration
  7. public safety notification on exosome products — U.S. Food and Drug Administration
  8. preliminary study of 16 patients — PubMed Central
  9. 2025 case report — PubMed Central
  10. 2025 case report — PubMed Central
  11. 2026 expert consensus on PDLLA-HA 200 (Juvelook Volume) — PubMed Central
  12. patient page on dermal fillers — U.S. Food and Drug Administration

Frequently asked questions

Q. How are Juvelook and exosomes regulated differently?

A. Juvelook is a named PDLLA and HA product line with stated contents; its manufacturer describes it as a class 4 medical device in Korea and lists its use as injection under the skin for temporary improvement of facial wrinkles in adults. For exosomes, the FDA says products meant to treat diseases or conditions generally need FDA approval and that there are currently no FDA-approved exosome products.

Q. What are exosomes?

A. A 2026 systematic review describes them as tiny extracellular vesicles from different cell types. In skin studies they come from human or plant sources, most often mesenchymal stem cells.

Q. Are all exosome products the same?

A. No. A 2026 scoping review found that commercial cosmetic exosome products varied in source and gave minimal information on isolation, processing or shelf life.

Q. Does the FDA rule apply in Korea?

A. No. The FDA says it does not have oversight of treatments done in other countries, and it advises learning about the regulations that cover products in the country where you are treated.

Q. How strong is the evidence for each?

A. Small for both. Reviews of exosomes describe few human studies, small samples and short follow-up. The Juvelook studies cited here are lab work, case reports and small studies, some supported by the manufacturer.

Q. What warning signs need care right away?

A. The FDA advises seeking immediate medical attention after a filler injection for unusual pain, vision changes, a white, gray or blue look to the skin near the injection site, or any signs of a stroke. It also notes that side effects can appear weeks, months or years later.

Treatment guide for this topic

Kim Simon Jang-ju

Kim Simon Jang-ju Head Physician

JANGJU KIM

Head Physician Kim Simon Jang-ju practices at STON Clinic, LOTTE HOTEL in Myeongdong (from December 1, 2026).

Career / Education

  • Current) Head Physician (practicing at STON Clinic Myeongdong and Beautystone Clinic Hapjeong; Myeongdong from Dec 1, 2026)
  • Graduated from Kyung Hee University College of Medicine
View profile

Comments